WQ
BMRN icon

Wealth Quarterback’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wealth Quarterback’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$5K Hold
60
– – ﹤0.01% 586
2021
Q2 		$6K Buy
+60
New +$4.76K ﹤0.01% 561

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wealth Quarterback's BMRN Position: Q3 2021 in Review

Wealth Quarterback held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2021 at 60 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #586.

Wealth Quarterback first reported a position in BMRN in Q2 2021 and has held it in 2 quarters since. The position peaked at $6K in Q2 2021. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

  • Wealth Quarterback held 60 shares of BioMarin Pharmaceuticals worth $5K as of Q3 2021.
  • Wealth Quarterback left its BioMarin Pharmaceuticals share count unchanged in Q3 2021.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Wealth Quarterback's portfolio in Q3 2021, its #586 holding.
  • Wealth Quarterback first reported a position in BioMarin Pharmaceuticals in Q2 2021 and has held it in 2 quarters since.
  • Wealth Quarterback's BioMarin Pharmaceuticals position peaked at $6K in Q2 2021.
  • 511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Wealth Quarterback's 13F filing for Q3 2021, filed 17 Nov 2021.